Table 2.

Differences between the CREST and the Guidant Corporation/FDA analysis

Aspect of the trial	Superiority (CREST)	Equivalence (Guidant Corporation/FDA analysis)
Hypothesis format	Traditional	Equivalency
Primary events	Stroke, myocardial infarction, or death in 30 days;	Stroke, myocardial infarction, or death in 30 days;
	ipsilateral stroke thereafter	ipsilateral stroke thereafter
Follow-up	Variable follow up (1-4 years)	1-year follow up
Statistical comparison	Differences in hazard of event	Event rate at 1 year